№ lp_1_2_01980
File format: docx Character count: 88369 File size: 92 KB
This document reports on the appeal hearing process and decision regarding the use of isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma in the UK.
Year: 2024
Region / city: United Kingdom
Topic: Health technology assessment
Document type: Appeal hearing report
Organization: National Institute for Health and Care Excellence (NICE)
Author: NICE
Target audience: Healthcare professionals, industry representatives, public
Period of validity: Not specified
Approval date: 23 September 2024
Date of changes: Not specified
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.

Don’t have cryptocurrency yet?

You can still complete your purchase in a few minutes:
  1. Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
  2. In the app, tap Send.
  3. Select network, paste our wallet address.
  4. Send the exact amount shown above.
After sending, paste your TXID (transaction ID) and your email to receive the download link. Need help? Contact support and we’ll guide you step by step.

The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCESINGLE TECHNOLOGY APPRAISALAPPEAL HEARINGAdvice on ruxolitinib for treating non-segmental vitiligo in people 12 years and over [ID3998]: Decision of the panel
Year: 2024
Region / City: United Kingdom
Topic: Health Technology Assessment
Document Type: Appeal Hearing Summary
Organization / Institution: National Institute for Health and Care Excellence (NICE)
Author: Dr Biba Stanton, Chair, NICE
Target Audience: Healthcare professionals, policy makers, stakeholders in healthcare assessments
Period of validity: Not specified
Date of approval: Not specified
Date of amendments: Not specified
Topics: isatuximab ID4067 EXCELLENCESINGLE